Background Image

Latest News

AMR Centre to partner with US biotech company

21 September 2017

AMR Centre to partner with US biotech company

The AMR Centre at Alderley Park has signed a co-development deal with a US biotech company.

The research and development facility, which specialises in antibiotics and diagnostics, has partnered with Massachusetts-based clinical-stage drug development company Microbiotix Inc.

As part of the agreement, the two will combine resources and leverage their antimicrobial R&D expertise to accelerate the development of Microbiotix's T3SS inhibitor project. The AMR Centre will provide up to $1.1m (£810,900) of technical support, alongside $1.6m (£1.18m) of further funding.

Dr Pete Jackson, executive director of the AMR Centre, said: "We are pleased to be working with Microbiotix to help address the critical, unmet need for therapies targeting drug resistant gram-negative bacteria.

"This is very much a co-development and as such our UK-based scientists are actively working on what candidates to take forward. We believe that this innovative project, which targets a World Health Organisation Priority 1 and ESKAPE pathogen, has the potential to reduce the threat of antimicrobial resistance."

Terry Bowlin, president and chief executive of Microbiotix, added: "This agreement with the AMR Centre will significantly accelerate our ability to deliver a pre-clinical candidate."